New Focus for Boehringer Ingelheim and Lilly Alliance
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance ®Alliance to focus combined expertise and investment to maximise Jardiance ®for people with type 2 diabetes, heart failure, and chronic kidney diseaseAlliance to continue to include three product families – empagliflozin, linagliptin and insulin glargine
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Failure | Insulin | Jardiance | Lantus | Research | Urology & Nephrology